EVEROLIMUS
NDC 60219-2281, everolimus, tablet, for suspension, from Amneal Pharmaceuticals NY LLC.
- Product NDC
- 60219-2281
- Status
- Listed
- Labeler
- Amneal Pharmaceuticals NY LLC
- Dosage form
- TABLET, FOR SUSPENSION
- Route
- ORAL
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application
- ANDA218863
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/60219-2281 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- EVEROLIMUS5 mg/1
Pharmacologic classes
Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Decreased Immunologic Activity [PE]; Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; mTOR Inhibitor Immunosuppressant [EPC]; mTOR Inhibitors [MoA]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 60219-2281-2 | 60219228102 | 4 BLISTER PACK in 1 CARTON (60219-2281-2) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACK (60219-2281-1) |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
FDA label sections
GET /v1/drugs/labels/6f1ae129-c21e-4c25-84c1-a6757d9a7eb2
Use it
Look up 60219-2281 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/60219-2281 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 60219-2281. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.